Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology
Celularity Inc. - Class A (CELU)
Company Research
Source: GlobeNewswire
FLORHAM PARK, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced a key publication in the April 4, 2025, issue of the prestigious peer-reviewed journal Frontiers in Immunology, the official journal of the International Union of Immunological Societies. In “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease,” Celularity scientists discuss how aging may influence the battle between the immune system and cancer, and the implications of senoablative Natural Killer, or NK, cells in disease progression. They emphasize that “preserving the function of NK cells during aging is essential for promoting healthy aging and longevity.” They conclude the publication by discussing the potential of adoptive NK cell therapy as a countermeasure to age-related decline in immunological function, a condition called immunosenescence. Robert J. Hariri, M.D., Ph
Show less
Read more
Impact Snapshot
Event Time:
CELU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CELU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CELU alerts
High impacting Celularity Inc. - Class A news events
Weekly update
A roundup of the hottest topics
CELU
News
- Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision [Yahoo! Finance]Yahoo! Finance
- Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic VisionGlobeNewswire
- Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye CareGlobeNewswire
- Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery DiseaseGlobeNewswire
- Michel Dard of BioCellgraft Wins Business Worldwide Magazines 2025 CEO Award [Yahoo! Finance]Yahoo! Finance
CELU
Sec Filings
- 12/5/25 - Form 8-K
- 11/21/25 - Form 4
- 11/21/25 - Form 4
- CELU's page on the SEC website